AMRN Amarin Corp

RNS Number:0503Y
Amarin Corporation Plc
08 June 2007





        AMARIN RECEIVES NASDAQ NOTIFICATION RELATED TO MINIMUM BID PRICE


LONDON, United Kingdom, June 8, 2007 Amarin Corporation plc (NASDAQ: AMRN)
("Amarin" or the "Company") today announced that it has received a Nasdaq staff
deficiency letter indicating that the Company is not in compliance with the
minimum bid price requirement for continued listing set forth under Nasdaq
Marketplace Rule 4320(e)(2)(E)(ii). As previously disclosed, Amarin expected to
receive this letter which is customary practice when a Nasdaq quoted company's
closing share price has been less than $1 for 30 consecutive trading days. The
closing price of Amarin's American Depository Shares ("ADSs") has been less than
$1 since April 24, following the announcement of the top-line results of
Miraxion's two phase III trials in Huntington's disease.

The Nasdaq letter has no effect on the listing of Amarin's ADSs at this time,
and its ADSs will continue to trade on the Nasdaq Capital Market under the
symbol "AMRN".

Amarin will be provided with 180 calendar days, or until December 3, 2007, to
regain compliance. If, at any time before December 3, 2007, the bid price of
Amarin's ADSs closes at $1.00 per share or more for a minimum of 10 consecutive
business days, Nasdaq will provide written notification that Amarin complies
with the Rule. If compliance with the Rule cannot be demonstrated by December 3,
2007, Amarin will be afforded an additional 180 calendar day compliance period
if Nasdaq determines at that time that the Company meets the remaining Nasdaq
Capital Market initial listing criteria in Rule 4320(e), except for the bid
price requirement. The Company currently meets all other initial listing
criteria in Rule 4320(e). Compliance can be achieved during this additional
compliance period by satisfying the applicable standard for a minimum of 10
consecutive business days. If the Company is not eligible for an additional
compliance period, Nasdaq will provide written notification that the Company's
securities will be delisted. At that time, the Company may appeal Nasdaq's
determination to delist its securities to a Listing Qualifications Panel.

Rick Stewart, Amarin's Chief Executive Officer, commented, "We are resolutely
committed to rebuilding shareholder value and are already making good progress
with our four key development programs, three of which will potentially be in
phase II trials next year. We plan to expand these four programs by bringing
forward other development opportunities in our development pipeline and also
through accessing new programs through in-licensing and acquisition."

Mr. Stewart continued, "We have the resources and infrastructure in place to
capitalize on the value opportunity that our pipeline offers. We recently
strengthened our management team with the hiring of Declan Doogan as President,
R&D, formerly Senior Vice President and Head of Worldwide Development at Pfizer
Global Research and Development and Paul Duffy as President, U.S. Commercial
Operations, formerly U.S. National Sales Director-Neuroscience at Novartis. We
also recently strengthened our balance sheet substantially with the completion
of a financing with Southridge Capital together with a significant investment in
the company by Amarin's directors and officers."


About Amarin

Amarin is committed to improving the lives of patients suffering from diseases
of the central nervous system.  Our goal is to be a leader in the research,
development and commercialization of novel drugs that address unmet patient
needs.

Amarin's core development pipeline includes, in addition to Miraxion for several
therapeutic indications, four other key development programs in Parkinson's
disease, epilepsy seizures, memory and cognition and our proprietary
pre-clinical combinatorial lipid program.

Amarin has its primary stock market listing in the U.S. on the Nasdaq Capital
Market ("AMRN") and secondary listings in the U.K. and Ireland on AIM ("AMRN")
and IEX ("H2E"), respectively.

For press releases and other corporate information, visit the Amarin website at
http://www.amarincorp.com. Information on our website does not form part of this
press release.


Contacts:
Amarin
+44 (0) 207 907 2442
Rick Stewart, Chief Executive Officer
Alan Cooke, President and Chief Financial Officer
investor.relations@amarincorp.com

Investors:
Lippert/Heilshorn & Associates, Inc.
Anne Marie Fields, +1 212 838 3777

Media:
Powerscourt
+44 (0) 207 250 1446
Rory Godson
Victoria Brough


Disclosure Notice:

The information contained in this document is as of June 8, 2007. Amarin assumes
no obligation to update any forward-looking statements contained in this
document as a result of new information or future events or developments. This
document contains forward-looking statements about Amarin's financial condition,
results of operations, business prospects and products in research that involve
substantial risks and uncertainties. You can identify these statements by the
fact that they use words such as "will", "anticipate", "estimate", "expect",
"project", "forecast", "intend", "plan", "believe" and other words and terms of
similar meaning in connection with any discussion of future operating or
financial performance or events. Among the factors that could cause actual
results to differ materially from those described or projected herein are the
following: risks relating to the Company's ability to maintain its Nasdaq
listing (including the risk that the Company may not able to achieve compliance
with the Nasdaq minimum bid price and/or other continued listing criteria within
the required timeframe or at all and the risk that the Company may not be able
to successfully appeal a Nasdaq delisting determination); the success of
Amarin's research and development activities; decisions by regulatory
authorities regarding whether and when to approve Amarin's drug applications, as
well as their decisions regarding labeling and other matters that could affect
the commercial potential of Amarin's products; the speed with which regulatory
authorizations, pricing approvals and product launches may be achieved; the
success with which developed products may be commercialized; competitive
developments affecting Amarin's products under development; the effect of
possible domestic and foreign legislation or regulatory action affecting, among
other things, pharmaceutical pricing and reimbursement, including under Medicaid
and Medicare in the United States, and involuntary approval of prescription
medicines for over-the-counter use; Amarin's ability to protect its patents and
other intellectual property; claims and concerns that may arise regarding the
safety or efficacy of Amarin's product candidates; governmental laws and
regulations affecting Amarin's operations, including those affecting taxation;
Amarin's ability to maintain sufficient cash and other liquid resources to meet
its operating requirements; general changes in International and U.S. generally
accepted accounting principles; growth in costs and expenses; and the impact of
acquisitions, divestitures and other unusual items. A further list and
description of these risks, uncertainties and other matters can be found in
Amarin's Form 20-F for the fiscal year ended December 31, 2006, filed with the
SEC on March 5 2007, Amarin's statutory annual report for the year ended 31
December, 2006 furnished on a Form 6-K to the SEC on May 9, 2007 and in its
Reports of Foreign Issuer on Form 6-K furnished to the SEC.


Ends.



                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
STRLVLFBDQBLBBX

Amarin (LSE:AMRN)
Historical Stock Chart
From Jun 2024 to Jul 2024

Amarin (LSE:AMRN)
Historical Stock Chart
From Jul 2023 to Jul 2024